CBD vs. CBN: Understanding the Key Differences & Benefits

Cannabidiol (CBD) and cannabinol (CBN) are two of over 100 cannabinoids in Cannabis sativa. While structurally similar, their effects, research base, and legal status differ significantly. Here's a science-based comparison.

Chemical Origin

• CBD: Directly biosynthesized from CBDA (acidic precursor) in trichomes. Abundant in hemp (Type III cannabis).
• CBN: Primarily a degradation product of THC via oxidation/heat/light. Minimal in fresh plant; increases with age/storage.

Psychoactivity

• CBD: Non-intoxicating. Does not bind CB1 receptors directly; negative allosteric modulator—may reduce THC's high.
• CBN: Weak CB1 partial agonist (~10% THC affinity). Mild sedation reported; not a "high" at typical doses.

Therapeutic Evidence

Condition	CBD Evidence	CBN Evidence
Epilepsy (Dravet, Lennox-Gastaut)	Strong: FDA-approved (Epidiolex)	Preclinical only
Anxiety	Moderate: RCT support (300–600 mg)	Anecdotal; limited data
Sleep	Mixed: dose-dependent (low=alerting, high=sedating)	Promising: sedation via CB1/TRPA1; human data scarce
Pain/Inflammation	Moderate: neuropathic, inflammatory (topical + oral)	Preclinical: anti-inflammatory, myorelaxant
Neuroprotection	Strong preclinical (ALS, PD, AD models)	Preclinical: ALS, TBI models
Appetite	Neutral/slight decrease	Stimulates appetite (THC-like)

Safety & Side Effects

• CBD: Generally well-tolerated. Dose-dependent: diarrhea, fatigue, appetite/weight changes, elevated LFTs. Drug interactions via CYP450 (3A4, 2C19) — caution with warfarin, antiepileptics, immunosuppressants.
• CBN: Limited human safety data. Theoretical: sedation, dizziness, dry mouth. Likely similar CYP interactions.

Legal Status (US)

• CBD: Hemp-derived (<0.3% THC) federally legal per 2018 Farm Bill. FDA regulates as drug (Epidiolex) or cosmetic; not approved as dietary supplement/food additive.
• CBN: Not explicitly scheduled. If derived from hemp, arguably legal; if from marijuana, Schedule I. State laws vary.

Product Considerations

• Certificate of Analysis (COA): Mandatory—verify cannabinoid potency, pesticides, heavy metals, solvents, microbes.
• Full-spectrum vs. isolate: Entourage effect theory; full-spectrum contains trace THC (<0.3%).
• Dosing: CBD: 25–100 mg/day typical; CBN: 5–20 mg (often combined 1:1 or 2:1 CBD:CBN for sleep).

Bottom Line

CBD has robust evidence for epilepsy, growing data for anxiety/pain. CBN is promising for sleep/appetite but lacks human trials. Neither is a cure-all. Consult a clinician knowledgeable in cannabinoid therapeutics, especially if on medications.